Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 15.33% | Hold | 1,831,035 | $88.48 | $162M | — | — |
| INSM - Insmed | 14.07% | Hold | 5,889,491 | $25.25 | $149M | — | — |
| UTHR - United Therapeutics | 12.31% | Reduce −8.2% | 575,907 | $225.87 | $130M | −51,607 | −$8M |
| FOLD - Amicus | 12.11% | Hold | 10,524,022 | $12.16 | $128M | — | — |
| BIIB - Biogen | 9.27% | Hold | 381,282 | $257.01 | $98M | — | — |
| PRTA - Prothena | 7.57% | Hold | 1,657,458 | $48.25 | $80M | — | — |
| Revance Therapeutics | 5.67% | Hold | 5,228,609 | $11.47 | $60M | — | — |
| Staar Surgical | 5.23% | Hold | 1,374,822 | $40.18 | $55M | — | — |
| ACAD - Acadia Pharmaceuticals | 4.74% | Hold | 2,405,793 | $20.84 | $50M | — | — |
| Sage Therapeutics | 1.96% | Add +17.0% | 1,005,776 | $20.58 | $21M | +146,259 | −$20M |
| EHTH - Ehealth | 1.92% | Hold | 2,739,379 | $7.40 | $20M | — | — |
| ALGN - Align Technology | 1.61% | Reduce −25.3% | 55,705 | $305.32 | $17M | −18,900 | −$9M |
| ALKS - Alkermes | 1.60% | Hold | 603,400 | $28.01 | $17M | — | — |
| Sarepta Therapeutics | 1.08% | Hold | 94,030 | $121.22 | $11M | — | — |
| NVCR - Novocure | 1.01% | Add +14.2% | 660,275 | $16.15 | $11M | +82,157 | −$13M |
| ANAB - Anaptysbio | 0.73% | Hold | 431,224 | $17.96 | $8M | — | — |
| Karyopharm Therapeutics | 0.72% | Hold | 5,675,876 | $1.34 | $8M | — | — |
| Nevro | 0.70% | Add +107.7% | 386,832 | $19.22 | $7M | +200,573 | +$3M |
| SNDX - Syndax Pharmaceuticals | 0.65% | Reduce −22.9% | 472,600 | $14.52 | $7M | −140,000 | −$6M |
| Gossamer Bio | 0.51% | Add +88.5% | 6,530,288 | $0.8328 | $5M | +3,065,136 | +$1M |
| CYTK - Cytokinetics | 0.31% | Hold | 111,717 | $29.46 | $3M | — | — |
| RLMD - Relmada Therapeutics | 0.21% | Hold | 732,400 | $3.00 | $2M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.19% | Hold | 64,700 | $31.60 | $2M | — | — |
| TVTX - Travere Therapeutics | 0.14% | Hold | 166,069 | $8.94 | $1M | — | — |
| VNDA - Vanda Pharmaceuticals | 0.11% | Reduce −13.9% | 278,985 | $4.32 | $1M | −45,088 | −$930K |
| ALDX - Aldeyra Therapeutics | 0.10% | Hold | 160,800 | $6.68 | $1M | — | — |
| Kezar Life Sciences | 0.07% | Hold | 656,200 | $1.19 | $781K | — | — |
| Holding | 0.04% | Hold | 27,100 | $14.05 | $381K | — | — |
| URGN - Urogen Pharma | 0.03% | Hold | 24,500 | $14.01 | $343K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Gritstone Oncology | 0.10% | Exit | 0 | $1.95 | $1M | −666,127 | −$1M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2